Cite
HARVARD Citation
Wollenberg, A. et al. (2021). Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. British journal of dermatology. pp. 437-449. [Online].